The Ideal Way to Use Quizartinib to Treat AML

January 21, 2014
Mark J. Levis, MD, PhD

Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Clinical Pearls:

  • The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML
  • Studies using “not as effective” FLT3 inhibitors still show a considerable amount of efficacy with this procedure
  • Patients should be treated into remission until the patient can receive an allogeneic transplant and then a FLT3 inhibitor